In various aspects and embodiments, the invention provides a method of controlling at least one cellular process in a mammalian cell via self-assembly of a synthetic organelle from expression of a scaffold protein capable of undergoing liquid-liquid phase separation (LLPS) tagged with a coiled coil. The method also comprises inserting one or more coiled coil or dimerization tags into the genome of a target mammalian cell; tags are operatively linked to at least one cellular decision making protein, thereby forming a sequesterable construct upon scaffold expression and controlling at least one cellular process.

Anti-VASA antibodies (mAbs), particularly humanized mAbs that specifically bind to VASA with high affinity, are disclosed. The amino acid sequences of the CDRs of the light chains and the heavy chains, as well as consensus sequences for these CDRs, of these anti-VASA mAbs are provided. The disclosure also provides nucleic acid molecules encoding the anti-VASA mAbs, expression vectors, host cells, methods for making the anti-VASA mAbs, and methods for expressing the anti-VASA mAbs. Finally, methods of using the anti-VASA mAbs to isolate and/or purify cells expressing VASA are disclosed.

The invention relates to a method for preventing, ameliorating or treating disease caused by dengue virus in a subject in need thereof comprising administering to the subject a dengue vaccine formulation in combination with a NS3 helicase polypeptide and/or fragment(s) thereof, wherein said method comprises stimulating humoral as well as cell-mediated immunity to the dengue virus in the subject.

Methods for screening to identify agents capable of modulating DDX5 polypeptide activity are encompassed herein as are methods for using such agents to treat subjects afflicted with T.sub.H17-mediated inflammatory conditions and autoimmune diseases including, without limitation, Crohn's disease, ulcerative colitis, multiple sclerosis, rheumatoid arthritis, and psoriasis and methods for using such agents to treat subjects afflicted with cancer.

The invention provides a chimeric enzyme comprising at least one catalytic domain of a RNA triphosphatase, at least one catalytic domain of a guanylyltransferase, at least one catalytic domain of a N.sup.7-guanine methyltransferase, and at least one catalytic domain of a DNA-dependant RNA polymerase. The invention also provides pharmaceutical composition comprising said chimeric enzyme and uses of said chimeric enzyme.

The present invention relates to a pharmaceutical composition for the prevention or treatment of cancer, comprising a DEAD-box helicase 54 (DDX54) inhibitor and a cancer immunotherapy agent, and to a combination therapy of cancer immunotherapy. The DDX54 inhibitor according to the present invention can enhance the efficacy of cancer immunotherapy when used in combination with a cancer immunotherapy agent, and the composition containing the DDX54 inhibitor and a cancer immunotherapy agent inhibits proliferation of cancer, which is a key characteristic thereof, and simultaneously inhibits a signal transduction pathway known as an immune evasion mechanism, and thus may be provided for the prevention or treatment of cancer.

Immunogenic compositions and methods of their use in eliciting immune responses to coronaviruses, such as SARS-CoV-2 are provided.

Compositions and methods for the preparation of immobilized enzymes for use in biocatalytic processes are provided. More specifically, the immobilized enzyme systems are covalently cross-linked biomolecular condensates that stabilize the enzymes without impeding their effectiveness as biocatalyst.